PremiumCompany AnnouncementsShionogi and F2G Post Positive Phase 3 Results for Novel Antifungal Olorofim1d ago
PremiumRatingsUeda Boosts Shionogi to Buy, Raising 12‑Month Target to ¥3,400 on Stronger HIV Franchise and Xocova Upside4d ago
Ueda Boosts Shionogi to Buy, Raising 12‑Month Target to ¥3,400 on Stronger HIV Franchise and Xocova Upside